SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
SMP-986 is a compound being developed for the treatment of overactive bladder syndrome
(OABS). This clinical study is designed to test the hypothesis that SMP-986 at doses of 20mg,
40mg, 80mg or 120mg provides greater symptom relief in OABS compared to placebo. The
hypothesis will be tested by measuring the change in mean voids/24 hrs after treatment with
SMP-986 compared to placebo, as well comparing the change in: the severity of urgency
episodes, mean number of urgency episodes/24 hr, mean number of incontinence episodes/24 hr
and the mean void volume/void between SMP-986 and placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Sunovion
Collaborators:
ClinPhone, Inc. Covance Dainippon Sumitomo Pharma America ICON Clinical Research PPD